Tempus AI TEM continues to expand its leadership in precision medicine through a series of impactful research initiatives and clinical validations. Throughout 2025 and early 2026, the company reported ...
Hello, and thank you for standing by. At this time, I would like to welcome everyone to the CareDx Investor Webinar Call. [Operator Instructions] I would now like to turn the conference over to ...
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...
Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio CareDx, Inc. (Nasdaq: CDNA) — The ...
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...
A total of 641 eligible cases were enrolled from June 2022 to October 2023 from seven hospitals in China. The sensitivity rates for all syndromes ranged from 70.37% to 92.00%, with the highest rate ...
MENLO PARK, Calif.--(BUSINESS WIRE)--#NatureMedicine--OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic ...
About The Study: In an average-risk colorectal cancer screening population, a blood-based test demonstrated acceptable accuracy for colorectal cancer detection, but detection of advanced precancerous ...
Tesla's upcoming affordable models could just be stripped-down versions of existing cars, something already speculated, but propped up during Tesla's quarterly earnings call. The models will be built ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results